Now Playing
Opinion|Videos|August 1, 2024
Emerging Agents in IPF Treatment
Author(s)Steven D. Nathan, MD
Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF). Which are you most excited about? What is the potential impact these agents, if approved, could have on the IPF treatment landscape?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
Medicaid Cuts and Caregiving in Congress: Andy Kim
3
COPD Disease Stability Emerges as a Treatment Target in GOLD 2026
4
Patient Fit Matters Most When Choosing the Right COPD Inhaler
5